These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 4633969)

  • 21. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
    Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
    Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunogenic properties and specificity of pseudomonas aeruginosa polyvalent vaccine].
    Schiller B; Lysakowska E; Owczarska K
    Med Dosw Mikrobiol; 1981; 33(2):91-6. PubMed ID: 6170849
    [No Abstract]   [Full Text] [Related]  

  • 23. [Results of using a polyvalent vaccine against Pseudomonas aeruginosa in patients with burns treated at various therapeutic centers in Poland].
    Bukowska D; Serafińska D; Zietkiewicz W; Rudowski W; Hoffman S; Uszyński H; Molski M; Hess C; Jonecko A; Popiel D
    Pol Tyg Lek; 1986 Dec; 41(49):1549-52. PubMed ID: 3108869
    [No Abstract]   [Full Text] [Related]  

  • 24. [Investigations on the immunogenicity of Pseudomonas seruginosa strains of different serological O-groups].
    Meitert E; Meitert T
    Zentralbl Bakteriol Orig; 1968; 208(4):515-21. PubMed ID: 5000090
    [No Abstract]   [Full Text] [Related]  

  • 25. Exotoxins of Pseudomonas aeruginosa. 3. Characteristics of antitoxin A.
    Liu PV; Hsieh H
    J Infect Dis; 1973 Oct; 128(4):520-6. PubMed ID: 4200593
    [No Abstract]   [Full Text] [Related]  

  • 26. Recent investigations on Pseudomonas aeruginosa.
    Homma JY
    Jpn J Exp Med; 1971 Oct; 41(5):387-400. PubMed ID: 5002617
    [No Abstract]   [Full Text] [Related]  

  • 27. Vaccinations against Pseudomonas aeruginosa: active and passive alternatives.
    Bellanti JA; Zeligs BJ; Kulczycki LL
    Pediatr Pulmonol Suppl; 1997; 16():269-70. PubMed ID: 9443307
    [No Abstract]   [Full Text] [Related]  

  • 28. Polyvalent antisera to Pseudomonas ribosomal vaccines: protection of mice against clinically isolated strains.
    Lieberman MM; Wright GL; Wolcott KM; McKissock-Desoto DC
    Infect Immun; 1980 Aug; 29(2):489-93. PubMed ID: 6783532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mouse-protection experience with monovalent Pseudomonas aeruginosa vaccine.
    Sourek J; Výmola F; Zelenková L
    Zentralbl Bakteriol A; 1980 Mar; 246(3):353-62. PubMed ID: 6775443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative study of the protective properties of native and sorbed Pseudomonas aeruginosa anatoxins].
    Dziuban NF
    Mikrobiol Zh (1978); 1983; 45(6):85-7. PubMed ID: 6443863
    [No Abstract]   [Full Text] [Related]  

  • 31. [Infections in minks caused by Pseudomonas aeruginosa. Infection and vaccination trials].
    Karlsson KA; Kull KE; Svanholm R
    Nord Vet Med; 1971; 23(7):345-51. PubMed ID: 5004400
    [No Abstract]   [Full Text] [Related]  

  • 32. 40 years on: have we finally got a vaccine for Pseudomonas aeruginosa?
    Worgall S
    Future Microbiol; 2012 Dec; 7(12):1333-5. PubMed ID: 23231481
    [No Abstract]   [Full Text] [Related]  

  • 33. [Derivation and experimental evaluation of polyvalent corpuscular vaccine for prevention of infections caused by Pseudomonas aeruginosa. I. Development of polyvalent corpuscular vaccine].
    Moroz AF; Radkevich SA; Antsiferova NG; Brodinova NS
    Zh Mikrobiol Epidemiol Immunobiol; 1981; (8):44-9. PubMed ID: 6171956
    [No Abstract]   [Full Text] [Related]  

  • 34. Serologic and protective cross-reactivity of antisera to Pseudomonas aeruginosa extracellular slime glycolipoprotein.
    Yushkova NA; Kholodkova EV; Korobova TS; Stanislavsky ES
    Acta Microbiol Hung; 1986; 33(2):147-56. PubMed ID: 3101393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conjugate vaccines against Pseudomonas aeruginosa and malaria.
    Cryz SJ; Sadoff JC; Que JU
    Contrib Microbiol Immunol; 1989; 10():166-89. PubMed ID: 2510972
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical use of a Soviet polyvalent corpuscular pyocyanic vaccine for the prevention of Pseudomonas aeruginosa infection in thermal burn victims].
    Gerasimova LI; Moroz AF; Radkevich SA; Sveshnikov AI; Mizikin EV
    Khirurgiia (Mosk); 1980 Nov; (11):36-41. PubMed ID: 6777578
    [No Abstract]   [Full Text] [Related]  

  • 37. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers].
    Bbukowska D; Serafińska D; Rudowski W; Hoffman S; Olański W; Gardzińska E; Popiel D; Jedrzejczak G; Czarnecka I
    Pol Tyg Lek; 1989 Oct 23-Nov 6; 44(43-45):924-7. PubMed ID: 2518666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Döring G
    Int J Med Microbiol; 2010 Dec; 300(8):573-7. PubMed ID: 20940108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of pseudomonas respiratory infection in a surgical intensive care unit.
    Polk HC; Borden S; Aldrete JA
    Ann Surg; 1973 May; 177(5):607-15. PubMed ID: 4634109
    [No Abstract]   [Full Text] [Related]  

  • 40. Pulmonary host defenses. I. Analysis of protein and lipids in bronchial secretions and antibody responses after vaccination with pseudomonas aeruginosa.
    Reynolds HY; Thompson RE
    J Immunol; 1973 Aug; 111(2):358-68. PubMed ID: 4197982
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.